Trial Profile
CONSENT - Comparison of metfOrmin XR to IR as moNotherapy in the Newly diagnoSed Type 2 diabEtes Patients for the gastroiNtestinal Tolerability and Efficacy: a Randomized, Parallel Control, Open-label and Multicenter Study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Metformin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- Acronyms CONSENT
- Sponsors Merck KGaA
- 13 Jun 2017 Primary endpoint (Percentage of Subjects With Gastrointestinal Adverse Events During Treatment Period) has not been met, according to the results presented at the 77th Annual Scientific Sessions of the American Diabetes Association.
- 13 Jun 2017 Primary endpoint (Change From Baseline in HbA1c at Week 16) has been met, according to the results presented at the 77th Annual Scientific Sessions of the American Diabetes Association.
- 13 Jun 2017 Results presented at the 77th Annual Scientific Sessions of the American Diabetes Association.